Management of Predominantly Basophilic Differential Count

Diagnostic Approach

A predominantly basophilic differential count (≥20% basophils in peripheral blood) is highly indicative of chronic myeloid leukemia (CML) in accelerated phase and requires immediate hematologic workup including BCR::ABL1 testing, bone marrow examination, and cytogenetic analysis, as recommended by the European LeukemiaNet (ELN) and the International Consortium on Acute Leukemia (ICCL) 1, 2
Immediate mandatory testing for confirmed basophilia includes BCR::ABL1 transcript detection by RT-PCR to identify CML, as basophils ≥20% define accelerated phase by both ELN 2020 and ICCL 2022 criteria, with a high level of evidence 1, 2
Bone marrow aspirate and biopsy with morphology assessment for blast percentage, promyelocytes, and dysplastic features are necessary for diagnosis, according to the ELN guidelines 1, 2
Cytogenetic analysis (karyotyping) on bone marrow cells to identify t(9;22) Philadelphia chromosome and additional cytogenetic abnormalities is crucial for diagnosis and prognosis, as stated by the ICCL 1, 2

Initiate or escalate tyrosine kinase inhibitor (TKI) therapy immediately for CML in accelerated phase (basophils ≥20%), as this represents disease progression requiring more aggressive treatment than chronic phase, with a strong recommendation from the ELN 1, 2
Consider second-generation TKI (dasatinib, nilotinib, bosutinib) if patient was on imatinib, based on the ICCL guidelines 2
Evaluate for hematopoietic stem cell transplant candidacy, as accelerated phase has worse prognosis than chronic phase, according to the ELN 2
Monitor BCR::ABL1 transcript levels by RT-qPCR using international scale for treatment response assessment, with a high level of evidence 2

Cytoreductive therapy with hydroxyurea is recommended for patients with high thrombotic risk or symptomatic disease, with a moderate level of evidence from the American Society of Clinical Oncology (ASCO) 3
Target platelet count restoration to <400 × 10⁹/L as soon as possible if thrombocytosis present, based on the ASCO guidelines 3
Consider interferon-alpha for symptomatic patients, particularly those with intractable pruritus from basophil-mediated histamine release, with a low level of evidence 3

Do not delay BCR::ABL1 testing when basophils are ≥20%, as this defines accelerated phase CML requiring immediate treatment modification, with a high level of evidence from the ELN and ICCL 1, 2
Recognize that basophils >0.5% in bronchoalveolar lavage represents a completely different clinical context (mastocytosis in interstitial lung disease) and should not be confused with peripheral blood basophilia, according to the American Thoracic Society (ATS) 4, 5, 6

Repeat cytogenetic analysis if additional chromosomal abnormalities develop during therapy, as this may indicate progression, with a moderate level of evidence from the ELN and ICCL 1, 2
Assess for thrombotic complications given increased risk with myeloproliferative disorders, particularly splanchnic vein thrombosis, based on the ASCO guidelines 3